June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Role of acyl-coenzyme A: cholesterol transferase (ACAT1) in pathological angiogenesis
Author Affiliations & Notes
  • Modesto Antonio Rojas
    Vascular Biology Center, Augusta University, Augusta, Georgia, United States
    Research, Charlie Norwood VA Medical Center, Augusta, Georgia, United States
  • Isabella Santana
    Vascular Biology Center, Augusta University, Augusta, Georgia, United States
  • Tahira Lemtalsi
    Vascular Biology Center, Augusta University, Augusta, Georgia, United States
    Research, Charlie Norwood VA Medical Center, Augusta, Georgia, United States
  • William Caldwell
    Pharmacology and Toxicology, Augusta University, Augusta, Georgia, United States
  • Ruth B Caldwell
    Vascular Biology Center, Augusta University, Augusta, Georgia, United States
    Research, Charlie Norwood VA Medical Center, Augusta, Georgia, United States
  • Footnotes
    Commercial Relationships   Modesto Rojas, None; Isabella Santana, None; Tahira Lemtalsi, None; William Caldwell, None; Ruth Caldwell, None
  • Footnotes
    Support  NIH Grant RO1 EY011766, NIH Grant R01 EY030500, VA Grant I01BX003221
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 5408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Modesto Antonio Rojas, Isabella Santana, Tahira Lemtalsi, William Caldwell, Ruth B Caldwell; Role of acyl-coenzyme A: cholesterol transferase (ACAT1) in pathological angiogenesis. Invest. Ophthalmol. Vis. Sci. 2020;61(7):5408.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We performed studies to define the role of ACAT1 in vitreoretinal neovascularization (PVR). Lipid loading in macrophages increases intracellular levels of cholesterol esters (CEs) which promotes an inflammatory phenotype. During ischemia, macrophages are exposed to a microenvironment of variably oxidized lipids, cytokines, and growth factors. ACAT1, an enzyme localized in the macrophage endoplasmic reticulum is responsible for cholesterol esterification with fatty acids and formation of CEs. During ischemic stress, macrophages increase their uptake of oxidized low-density lipoprotein cholesterol leading to increased ACAT1 activity and formation of toxic levels of CEs. This promotes expression of inflammatory factors like the amplifier of inflammatory signaling TREM-1 (triggering receptor expressed in myeloid cells-1) and M-CSF (macrophage colony-stimulating factor) and growth factors like VEGF. TREM-1, MCSF, and VEGF are major players PVR but the role of ACAT1 is completely unknown.

Methods : We examined the role of ACAT1 in PVR using both in vitro and in vivo models. For in vitro studies, human macrophages were subjected to hypoxia (1% O2) or normoxia (21% O2) for 16 hrs and treated with the ACAT inhibitor N-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-L-phenylalanine, methyl ester (10µg/ml) or vehicle. Expression of TREM-1, M-CSF, and VEGF was determined by western blot. In vivo studies used a mouse model of oxygen-induced retinopathy (OIR). Neonatal mice were maintained in 75% oxygen from postnatal day 7 (P7) to P12 and normoxia to P17 and treated with the ACAT inhibitor (10 mg/Kg, i.p) or vehicle (PBS) on alternate days from P7 to P16. Eyes were collected at P17 and prepared for retinal flat mount imaging, frozen sectioning, or western blot.

Results : Hypoxia in vitro or OIR in vivo induced significant increases in TREM-1, M-CSF, and VEGF expression (p<0.05). The latter increases were significantly inhibited by treatment with the ACAT inhibitor (p<0.05). The inhibitor treatment also reduced OIR-induced vitreoretinal neovascularization and improved physiological repair of the avascular zone as compared to the vehicle (p<0.05).

Conclusions : Hypoxia-induced increases in PVR are associated with increases in the expression of TREM-1, M-CSF, and VEGF require ACAT1 activity. Blockade of this pathway offers a new strategy for treatment and prevention of vascular injury during ischemic retinopathy

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×